Item 2.02 매우중요

실적 발표

Item 2.02.   Results of Operations and Financial Condition.   Regeneron Pharmaceuticals, Inc. (“ Regeneron ” or the “ Company ”) currently expects that its financial results calculated in accordance with U.S. generally accepted accounting principles (“ GAAP ”) and its non-GAAP financial results for the second quarter 2026 will include an acquired in-process research and development (“ IPR&D ”) charge of approximately $127 million on a pre-tax basis. This charge relates to up-front and opt-i...